The comparison of final tumour volumes between treated and untreated conditions revealed that Capmatinib induced a reduction in tumour volume only in mice injected with the PC3M ETV1 and PC3M ERG cell lines and not in control mice (Fig 4B). Here, ERG is linked to neoplasm.